VVOS: Vivos Therapeutics Forward P/E Multiple
The neutral geopolitical status of Vivos Therapeutics (VVOS) ensures stable growth in the US, which is confirmed by the dynamics of the company's forward P/E ratio. The current level of 0.00 captures the asset's latest values. The business is implementing eco-friendly polymers and energy efficiency into production, although it is being constrained by low insurance support and the slow adoption of dental devices for treating apnea.
Vivos Therapeutics, Inc. (VVOS) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- market capitalization information:
- book capitalization information:
- debt and liquidity details:
Total Debt to Capital Vivos Therapeutics|VVOS - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Vivos Therapeutics, Inc.|VVOS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Vivos Therapeutics|VVOS - Company Long-Term Liabilities|Company Short-Term Debts Vivos Therapeutics|Quick Ratio vivoslife.com
- financial results and valuation multiples details:
VVOS - Company Profit|Projected Future Earnings Vivos Therapeutics|VVOS - Business Payback Period|Forward P/E Multiple vivoslife.com|VVOS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Vivos Therapeutics, Inc|VVOS - Operating profit EBITDA|Earnings per share for the last twelve months Vivos Therapeutics|VVOS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months vivoslife.com|VVOS - Earnings per share increase in current year|Earnings growth forecast for next year Vivos Therapeutics
- sales and revenue indicators:
Fundamental valuation:VVOS Vivos Therapeutics Inc
The assessment of Vivos Therapeutics (VVOS) resilience to market downturns relies on the protected perimeter of the apnea treatment ecosystem featuring proprietary CARE devices. By analyzing the company's future P/E trajectory on GURU.Markets, an investor compares market capitalization with projected net income, which, at the current value of 0.00, allows for the filtering of short-term noise and the determination of the asset's fundamental value relative to expected earnings.
Competitors of Vivos Therapeutics
Forward P/E Multiple BSX|EW: Price to Expected Earnings Ratio|ResMed Corp - Projected Price to Earnings|Market Cap to Projected Earnings Insulet (PODD)|zimmerbiomet.com - Forward P/E Multiple|Projected Price to Earnings Ratio CooperCompanies|ALGN: Forward P/E Multiple|Projected Price to Earnings Ratio Globus Medical Corp (GMED)|TMDX (TransMedics Group Inc) - Forward P/E Multiple|Price to Future Earnings Ratio ATEC (Alphatec)|Projected Price to Earnings AORT (Artivion)|ENOV (Enovis Corp) - Future Price to Earnings Multiple|Future Price to Earnings Integra LifeSciences Inc. IART|ESTA - Projected Price to Earnings|Beta Bionics, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio IRADIMED CORPORATION|EMBC: Forward P/E Multiple|Price to Future Earnings Ratio TNDM|AXGN (Axogen Surgical) - Forward P/E Multiple|SI-BONE Corp (SIBN) - Market Cap to Projected Earnings|Forward P/E Multiple OFIX|Forward P/E Multiple bioventus.com (BVS)|Forward P/E Multiple KIDS (OrthoPediatrics Corp)|Forward P/E Multiple Treace Medical Concepts Inc TMCI|SRTA - Future Price to Earnings|CARL: Future Price to Earnings|RXST (RxSight, Inc.) - Projected Price to Earnings|ClearPoint Neuro Inc. - Future Price to Earnings Multiple|STXS (Stereotaxis Corporation) - Forward P/E Multiple|Projected Price to Earnings Ratio Neuronetics Inc. STIM|Future Price to Earnings Sight Sciences Inc. (SGHT)|Orchestra BioMed, Inc. (OBIO) - Forward Price to Earnings Multiple|Anika Therapeutics Inc. - Projected Price to Earnings|Forward P/E Multiple InspireMD, Inc. NSPR|Jin Medical International Ltd. - Forward P/E Multiple|Market Cap to Projected Earnings Vivani Medical VANI|Xtant Medical (XTNT) - Future Price to Earnings|Price to Expected Earnings Ratio NMTC (NeuroOne Medical Technologies Corp.)|Future Price to Earnings modular-medical.com|Projected Price to Earnings Ratio myomo.com MYO|Forward P/E Multiple COCH|NVNO - Projected Price to Earnings Ratio|Future Price to Earnings sintx.com SINT|TNON: Price to Future Earnings Ratio|LFWD: Projected Price to Earnings|autonomix.com - Market Cap to Future Earnings Ratio|INVO Bioscience, Inc. (IVF) - Future Price to Earnings|BBLG (Bone Biologics Corp.) - Future Price to Earnings|Projected Price to Earnings AXNX|Biolase Inc. (BIOL) - Market Cap to Projected Earnings|Future Price to Earnings Dynatronics Corp. (DYNT)|Forward P/E Multiple Paragon 28 (FNA)|Future Price to Earnings INVO Bioscience INVO
